Baker Bros. Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Baker Bros. Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-15,162	Closed	-$106K	–	134
2020 Q4	$106K	Hold	15,162	–	–	﹤0.01%	125
2020 Q3	$66K	Sell	15,162 -743	-5%	-$6.49K	﹤0.01%	120
2020 Q2	$147K	Hold	15,905	–	–	﹤0.01%	113
2020 Q1	$231K	Hold	15,905	–	–	﹤0.01%	108
2019 Q4	$188K	Hold	15,905	–	–	﹤0.01%	99
2019 Q3	$401K	Hold	15,905	–	–	﹤0.01%	105
2019 Q2	$405K	Hold	15,905	–	–	﹤0.01%	100
2019 Q1	$676K	Hold	15,905	–	–	﹤0.01%	93
2018 Q4	$231K	Hold	15,905	–	–	﹤0.01%	92
2018 Q3	$1.11M	Hold	15,905	–	–	0.01%	91
2018 Q2	$1.18M	Hold	15,905	–	–	0.01%	105
2018 Q1	$1.51M	Sell	15,905 -5,285	-25%	-$906K	0.01%	96
2017 Q4	$2.74M	Hold	21,190	–	–	0.02%	93
2017 Q3	$1.44M	Hold	21,190	–	–	0.01%	102
2017 Q2	$2M	Hold	21,190	–	–	0.02%	87
2017 Q1	$3.04M	Hold	21,190	–	–	0.02%	77
2016 Q4	$2.69M	Hold	21,190	–	–	0.03%	83
2016 Q3	$3.24M	Hold	21,190	–	–	0.03%	78
2016 Q2	$2.44M	Hold	21,190	–	–	0.03%	91
2016 Q1	$2.4M	Hold	21,190	–	–	0.03%	93
2015 Q4	$3.99M	Buy	21,190 +5,952	+39%	+$1.11M	0.03%	85
2015 Q3	$2.59M	Hold	15,238	–	–	0.02%	96
2015 Q2	$9.63M	Hold	15,238	–	–	0.08%	65
2015 Q1	$7.84M	Hold	15,238	–	–	0.07%	65
2014 Q4	$8.16M	Buy	+15,238	New	+$6.87M	0.08%	55

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baker Bros. Advisors's VIRX Position: Q1 2021 in Review

Baker Bros. Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2021, closing a stake of 15,162 shares — an estimated $106K sold.

Baker Bros. Advisors first reported a position in VIRX in Q4 2014 and held it in 25 quarters. The position peaked at $9.63M in Q2 2015. 50 funds tracked by Wall St. Rank hold VIRX as of Q1 2021.

Baker Bros. Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Baker Bros. Advisors sold 15,162 Viracta Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $106K.
Baker Bros. Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2014 and held it in 25 quarters.
Baker Bros. Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $9.63M in Q2 2015.
50 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Baker Bros. Advisors's 13F filing for Q1 2021, filed 17 May 2021.